MDR/XDR/PDR or DTR? Which definition best fits the resistance profile of Pseudomonas aeruginosa?

Epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: the EUROBACT-2 international cohort study

(2023) Alexis Tabah et al.   INTENSIVE CARE MEDICINE

Risk factors and outcomes of inpatients with carbapenem-resistant Pseudomonas aeruginosa bloodstream infections in China: a 9-year trend and multicenter cohort study

(2023) Qing Yuan et al.   Frontiers in Microbiology

Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study

(2023) Jinnethe Reyes et al.   Lancet Microbe

Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa

(2022) Cristina Lasarte-Monterrubio et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In vitro activity of imipenem/relebactam against Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal (SUPERIOR and STEP studies)

(2022) Marta Hernández-García et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)

(2021) Mical Paul et al.   CLINICAL MICROBIOLOGY AND INFECTION

A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)

(2020) Ivan Titov et al.   CLINICAL INFECTIOUS DISEASES

External Validation of Difficult-to-Treat Resistance Prevalence and Mortality Risk in Gram-Negative Bloodstream Infection using Electronic Health Record Data from 140 US Hospitals

(2019) Sameer S Kadri et al.   Open Forum Infectious Diseases

DTR, do we need a new definition?

(2019) Roger M Echols et al.   CLINICAL INFECTIOUS DISEASES

RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections

(2019) Johann Motsch et al.   CLINICAL INFECTIOUS DISEASES

Prognostic Utility of the New Definition of Difficult-to-Treat Resistance Among Patients With Gram-Negative Bloodstream Infections

(2019) Maddalena Giannella et al.   Open Forum Infectious Diseases

Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers

(2017) Tommaso Giani et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Predictors of mortality in patients with infections due to multi-drug resistant Gram negative bacteria: The study, the patient, the bug or the drug?

(2012) Konstantinos Z. Vardakas et al.   JOURNAL OF INFECTION

Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance

(2011) A.-P. Magiorakos et al.   CLINICAL MICROBIOLOGY AND INFECTION